San Jose, CA (PRWEB) June 22, 2009
Rising proportion of cancer population in both developed and developing countries is expected to enhance the demand for brachytherapy for cancer treatment. In particular, brachytherapy has emerged as the effective treatment option for prostate cancer patients, who have failed to achieve desirable results through surgery or external radiation therapy. With long-term clinical data offering support for the effectiveness of brachytherapy in reducing size of the tumor, the therapy is expected to gain strength. With indications for brachytherapy ranging from prostate cancer, head and neck cancer, cervical cancer, and breast cancer to coronary applications, the rapidly aging world population represents a strong demographic growth driver.
The United States represents the largest as well as the fastest growing market for brachytherapy. In the United States, increasing incidence of cancer cases and related mortality rates are contributing to the increasing demand for brachytherapy, as stated in the new report. Rising awareness about risks of surgery and external radiation therapy are fostering advancements in technologies and products for less invasive treatment for cancer. Growing uptake of brachytherapy is also attributed to the increasing success rates of prostate brachytherapy, breast brachytherapy, and head and neck brachytherapy procedures. Driven by the minimally invasive nature of the procedure, Implantable Prostate Seed Therapy is expected to continue posting healthy gains in the market.
Further, balloon brachytherapy for breast cancer treatment is expected to gain rapid acceptance among patients and physicians alike. Post-Operative Brachytherapy market is the fastest growing segment. Growing concerns over rising cancer levels, increasing awareness about adverse effects of EBRT, constant improvements in technologies and devices, and wider acceptance of brachytherapy are expected to boost prospects in the European post-surgical brachytherapy market.
Competition in the brachytherapy market is intensifying, particularly in the implantable prostate seed segment with Oncura Corp., CR Bard, NAS Medical, Theragenics Corporation, and Xoft, competing for a share of the lucrative market. Major players profiled in the report include Best Medical International Inc, BrachySciences Inc, C. R. Bard Inc, Core Oncology, Cytogen Corporation, Cytyc Corporation, Eckert & Ziegler Strahlen- und Medizintechnik AG, International Brachytherapy SA, Oncura, Inc., Theragenics Corporation Sirtex Medical Ltd, Varian Medical Systems Inc, Xoft Inc, among several others.
"Brachytherapy: A US and European Market Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of prevailing market issues and trends, competitive scenario, and recent industry activity in the brachytherapy market. Analytics for the period 2005-2015 provide a comprehensive understanding of markets including the United States and Europe. The markets are analyzed in terms of Number of Procedures (Thousands) and Annual Revenues (US$ Million) for the segments - Implantable Prostate Seed and Post-Surgical Brachytherapy.
For more details about this comprehensive market research report, please visit - http://www.strategyr.com/Brachytherapy_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Email press (at) StrategyR.com
Web Site http://www.StrategyR.com/
# # #